首页> 美国卫生研究院文献>Bentham Open Access >Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimers Disease
【2h】

Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimers Disease

机译:多功能药物作为阿尔茨海默氏病潜在药物候选药物的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is limited to the symptomatic treatment and its efficacy remains unsatisfactory. In view of the prevalence and expected increase in the incidence of AD, the development of an effective therapy is crucial for public health. Due to the multifactorial aetiology of this disease, the multi-target-directed ligand (MTDL) approach is a promising method in search for new drugs for AD. This review updates information on the development of multifunctional potential anti-AD agents published within the last three years. The majority of the recently reported structures are acetylcholinesterase inhibitors, often endowed with some additional properties. These properties enrich the pharmacological profile of the compounds giving hope for not only symptomatic but also causal treatment of the disease. Among these advantageous properties, the most often reported are an amyloid-β anti-aggregation activity, inhibition of β-secretase and monoamine oxidase, an antioxidant and metal chelating activity, NO-releasing ability and interaction with cannabinoid, NMDA or histamine H3 receptors. The majority of novel molecules possess heterodimeric structures, able to interact with multiple targets by combining different pharmacophores, original or derived from natural products or existing therapeutics (tacrine, donepezil, galantamine, memantine). Among the described compounds, several seem to be promising drug candidates, while others may serve as a valuable inspiration in the search for new effective therapies for AD.
机译:阿尔茨海默氏病(AD)是一种复杂的进行性神经退行性疾病。可用的治疗仅限于对症治疗,其疗效仍不令人满意。鉴于AD的患病率和预期的增加,开发有效的疗法对公共卫生至关重要。由于这种疾病的病因是多因素的,因此多靶标配体(MTDL)方法是寻找AD新药的一种有前途的方法。这篇评论更新了过去三年中发布的有关多功能潜在抗AD制剂开发的信息。最近报道的大多数结构是乙酰胆碱酯酶抑制剂,通常具有一些其他特性。这些特性丰富了化合物的药理作用,不仅希望对症治疗,而且可以对病因进行治疗。在这些有利的特性中,最常报告的是淀粉样蛋白β的抗聚集活性,β分泌酶和单胺氧化酶的抑制,抗氧化剂和金属螯合活性,NO释放能力以及与大麻素,NMDA或组胺H3受体的相互作用。大多数新型分子具有异二聚体结构,能够通过结合不同的原始或衍生自天然产物或现有治疗剂(他克林,多奈哌齐,加兰他敏,美金刚)的药效基团与多个靶标相互作用。在所描述的化合物中,有几种似乎是有前途的候选药物,而另一些则可以作为寻找AD新有效疗法的宝贵灵感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号